The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Shipilova N.N.
Pirogov Russian National Research Medical University of the Ministry of Health of the Russia, Moscow, Russia
Titova N.V.
Kafedra nevrologii i neĭrokhirurgii lechebnogo fakul'teta Rossiĭskogo gosudarstvennogo meditsinskogo universiteta, Moskva
Kokaeva Z.G.
Lomonosov Moscow State University, Moscow, Russia
Fedosova A.S.
Lomonosov Moscow State University, Moscow, Russia
Klimov E.A.
Lomonosov’s Moscow State University, Moscow, Russia
Katunina E.A.
Department of Neurology, Neurosurgery and Medical Genetics of the Pirogov Russian National Research Medical University of the Ministry of Health of the Russia, Moscow, Russia
A clinical and genetic study of impulsive-compulsive disorders in patients with Parkinson’s disease
Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(10): 4‑9
Views: 1099
Downloaded: 17
To cite this article:
Shipilova NN, Titova NV, Kokaeva ZG, Fedosova AS, Klimov EA, Katunina EA. A clinical and genetic study of impulsive-compulsive disorders in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry.
2018;118(10):4‑9. (In Russ.)
https://doi.org/10.17116/jnevro20181181014
Objective. To evaluate the frequency and spectrum of impulsive-compulsive disorders (ICDs) in patients with Parkinson’s disease (PD) without dopaminergic medication and among patients receiving dopaminergic replacement therapy, depending on personality type, genetic factors, and to determine the influence of ICDs on the development of other non-motor manifestations of the disease. Material and methods. Three hundred and eighty-six consecutive patients with idiopathic PD, including untreated patients with PD (de novo) and patients receiving dopaminergic replacement therapy during one year, were examined. ICDs were evaluated with QUIP and diagnostic criteria. Personality type and temperament features were assessed by the Eysenck personality inventory. Genotyping for the single nucleotide polymorphism rs141116007 in the DBH gene involved in the pathogenesis of PD and ICDs was performed. Results and conclusion. ICDs were identified in 20.2% patients with PD and in 4% patients of the de novo group. The most common (10.36%) behavioral disorder was a binge eating. The frequency of ICDs among patients with PD before the onset of dopamine replacement therapy increased by 1.03 times after one year treatment. Smoking and young age were risk factors for ICDs (p<0.05). The results of the study allowed the determination of social and neuropsychological risk factors for ICDs in patients with PD. The account of these features, as well as early detection of ICDs using screening questionnaires may help to personalize treatment of patients with PD and to prevent the risk of developing comorbid non-motor manifestations of the disease.
Authors:
Shipilova N.N.
Pirogov Russian National Research Medical University of the Ministry of Health of the Russia, Moscow, Russia
Titova N.V.
Kafedra nevrologii i neĭrokhirurgii lechebnogo fakul'teta Rossiĭskogo gosudarstvennogo meditsinskogo universiteta, Moskva
Kokaeva Z.G.
Lomonosov Moscow State University, Moscow, Russia
Fedosova A.S.
Lomonosov Moscow State University, Moscow, Russia
Klimov E.A.
Lomonosov’s Moscow State University, Moscow, Russia
Katunina E.A.
Department of Neurology, Neurosurgery and Medical Genetics of the Pirogov Russian National Research Medical University of the Ministry of Health of the Russia, Moscow, Russia
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.